13th Sep 2005 11:27
Provalis PLC13 September 2005 Provalis plc Notice of results Provalis plc (LSE: PRO), the international medical diagnostics andpharmaceuticals group, will be announcing preliminary results for the year ended30 June 2005 on Wednesday, 19 October 2005. 13 September 2005 For further details please contact: College Hill 020 7457 2020Corinna Dorward/ Adrian Duffield Provalis plc (LSE: PRO) (http://www.provalis.com) is an international healthcaregroup with two operating businesses:- • Medical Diagnostics - The business' principal products are in2it TMA1c and Glycosal(R), both diabetes diagnostic tests. In2itTMA1c is a fully automated, point of care, diabetes diagnostic, testing platform which has marketing clearance from the FDA in the US for use in both physicians' offices and at home on prescription. • Pharmaceuticals - sells and markets its own, and third party, branded, prescription medicines in the UK and Ireland to GPs and hospitals through its regionally managed sales force. The business' principal product is Diclomax(R), a medicine for use in the treatment of musculo-skeletal disorders, and it also sells products in the areas of osteoporosis, migraine and dermatology. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Statements in this announcement that relate to future plans, expectations,events, performances and the like are forward-looking statements as defined inthe US Private Securities Litigation Reform Act of 1995. Actual results ofevents could differ materially from those described in the forward-lookingstatements due to a variety of factors. Such factors include, among others: theviability of the Group's products, which are at various stages of development;the generation of sufficient operating cash flow by the Group's pharmaceuticaland medical diagnostic businesses to finance the ongoing development of thesebusinesses as well as the Group's research and development activities; thesuccess of the Group's research and development strategy and activities;uncertainties related to future clinical trial results and the associatedregulatory process; the execution and success of collaborative agreements withthird parties; availability and level of reimbursement for the Group's productsfrom government health administration authorities or other third-party payors;the rate of net cash utilisation within the Group and, hence, the Group'spossible need for additional capital in the short, medium and/or long term; theGroup's intellectual property position and the success of patent applicationsfor its products and technologies; the Group's dependence on key personnel;general business and economic conditions; the impact of future laws, regulationsand policies; stock market trends in the Group's sector; and other factorsbeyond the Group's control that may cause the Group's available capitalresources to be used more quickly than expected. These and other factors thatcould affect the Company's future results are more fully described in itsfilings with the US Securities and This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Proservice Bldg